High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma
High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma
复制标题
DOI：
10.1182/blood-2010-05-287664
复制
发表时间：
2011-02-10
期刊：
影响因子：
20.3
通讯作者：
Kupper, Thomas S.
中科院分区：
文献类型：
--
作者：
Clark, Rachael A.;Shackelton, Jeffrey B.;Kupper, Thomas S.
在早期皮肤T细胞淋巴瘤（CTCL）中，恶性T细胞局限于皮肤，难以分离和区分良性反应性细胞。我们发现CTCL皮肤病变的T细胞中含有大量的高分散的活化皮肤归巢T细胞，这在其他炎症性皮肤病中是没有观察到的。高散在T（T-HS）细胞在CD 4（+）蕈样肉芽肿（MF）中为CD 4（+），在CD 8（+）MF中为CD 8（+），并且在具有可识别的恶性V β克隆的患者中仅包含克隆T细胞。THS细胞存在于白血病CTCL患者的血液中，在没有血液受累的患者中不存在，并且仅包含克隆性恶性T细胞。克隆性THS细胞的存在与患者的皮肤疾病相关。克隆性THS细胞在体外循环血液置换清除的患者中发生凋亡，但在无反应的患者中持续存在。良性克隆性T细胞增殖映射到正常的低散射T细胞群。因此，MF和白血病CTCL中的恶性T细胞可以通过独特的散射谱来最终识别。这一观察结果将允许恶性T细胞的选择性研究，可用于区分MF患者与其他炎症性皮肤病患者，检测外周血受累，并监测对治疗的反应。（血。2011; 117（6）：1966-1976）
In early-stage cutaneous T-cell lymphoma (CTCL), malignant T cells are confined to skin and are difficult to isolate and discriminate from benign reactive cells. We found that T cells from CTCL skin lesions contained a population of large, high-scatter, activated skin homing T cells not observed in other inflammatory skin diseases. High-scatter T (T-HS) cells were CD4(+) in CD4(+) mycosis fungoides (MF), CD8(+) in CD8(+) MF, and contained only clonal T cells in patients with identifiable malignant V beta clones. THS cells were present in the blood of patients with leukemic CTCL, absent in patients without blood involvement, and contained only clonal malignant T cells. The presence of clonal THS cells correlated with skin disease in patients followed longitudinally. Clonal THS cells underwent apoptosis in patients clearing on extracorporeal photopheresis but persisted in nonresponsive patients. Benign clonal T-cell proliferations mapped to the normal low-scatter T-cell population. Thus, the malignant T cells in both MF and leukemic CTCL can be conclusively identified by a unique scatter profile. This observation will allow selective study of malignant T cells, can be used to discriminate patients with MF from patients with other inflammatory skin diseases, to detect peripheral blood involvement, and to monitor responses to therapy. (Blood. 2011; 117(6): 1966-1976)